Charles River Laboratories International, Inc. (CRL)
Charles River Gains 75.8% in a Year: What's Driving the Rally?
CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan
Charles River Laboratories International NYSE: CRL outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin and low-double-digit non-GAAP earnings-per-share growth.
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Is This the Right Time to Add CRL Stock to Your Portfolio?
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
Charles River Gains 88.6% in a Year: What's Driving the Rally?
CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.
International Markets and Charles River (CRL): A Deep Dive for Investors
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Charles River Laboratories International Q2 Earnings Call Highlights
Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.
CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market
Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.
Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?
Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
